<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00558701</url>
  </required_header>
  <id_info>
    <org_study_id>H-07-003</org_study_id>
    <secondary_id>I.2007.128</secondary_id>
    <nct_id>NCT00558701</nct_id>
  </id_info>
  <brief_title>Microcurrent for Healing Autogenous Skin Donor Sites</brief_title>
  <official_title>Prospective, Randomized, Controlled Study of the Efficacy of a Silver-coated Nylon Dressing Plus Active or Sham Microcurrent for Healing Autogenous Skin Donor Sites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United States Army Institute of Surgical Research</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Samueli Institute for Information Biology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>United States Army Institute of Surgical Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single-center, prospective, randomized, and controlled study evaluated the efficacy of
      silver-coated dressing with active microcurrent in comparison to silver-coated dressing with
      sham microcurrent on wound-closure time for autogenous skin donor sites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific aims of the study are to evaluate the impact of active versus sham direct
      microcurrent application to silver nylon dressings in the treatment of donor sites for
      partial thickness thermal injuries. The primary endpoint is wound-closure time
      (re-epithelialization of 90% or more of wound surface). A secondary endpoint was infection.
      Exploratory assessments of clinical outcomes, including inflammation, and pain medication
      (type, dosage, route, timing) will also be conducted.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Wound Healing</measure>
    <time_frame>20 days</time_frame>
    <description>Time to 90% confluent reepitheliazation of donor site, as indicator of wound healing</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Burns</condition>
  <arm_group>
    <arm_group_label>Microcurrent Stimulator + Silverlon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving active electrical stimulation (15-50 microamps) during treatment of skin donor sites with Silverlon wound contact dressing. Intervention is active electrical stimulation via microcurrent stimulator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Silverlon alone</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients receiving treatment of skin donor sites with Silverlon wound contact dressing alone (i.e., without active electrical stimulation)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microcurrent stimulator</intervention_name>
    <description>Microcurrent stimulation from 15-50 microamps</description>
    <arm_group_label>Microcurrent Stimulator + Silverlon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Silverlon Wound Contact Dressing</intervention_name>
    <description>Silver coated nylon dressing FDA approved for use on donor sites in burn patients</description>
    <arm_group_label>Microcurrent Stimulator + Silverlon</arm_group_label>
    <arm_group_label>Silverlon alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  between 18-65 years of age

          -  burn less than 30% total body surface area

          -  burns not involving donor site area

          -  you need skin grafting to cover burns

          -  agree not to use other electronic devices that generate current during your study
             participation

          -  agree to come back for follow up visits at least every other day after discharge from
             hospital until donor site is healed

        Exclusion Criteria:

          -  you have an illness that may affect how your wound heals such as diabetes, blood
             clotting disorder, cirrhosis, liver failure, peripheral vascular disease

          -  you are taking medications that could affect how your wound heals such as steroids,
             Plavix, Coumadin

          -  you have an infection of the skin or your bloodstream

          -  you are pregnant or nursing

          -  you are sensitive or allergic to silver or nylon

          -  your burn wounds are more than 30% of your total body surface area

          -  your site was previously harvested for grafting

          -  you have an implantable pacemaker device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leopoldo C Cancio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>United States Army Institute of Surgical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USAISR</name>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kauvar DS, Cancio LC, Wolf SE, Wade CE, Holcomb JB. Comparison of combat and non-combat burns from ongoing U.S. military operations. J Surg Res. 2006 May 15;132(2):195-200. Epub 2006 Mar 31.</citation>
    <PMID>16580688</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2007</study_first_submitted>
  <study_first_submitted_qc>November 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2007</study_first_posted>
  <results_first_submitted>August 21, 2015</results_first_submitted>
  <results_first_submitted_qc>April 26, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 6, 2016</results_first_posted>
  <last_update_submitted>April 26, 2016</last_update_submitted>
  <last_update_submitted_qc>April 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>burns</keyword>
  <keyword>donor site</keyword>
  <keyword>healing</keyword>
  <keyword>microcurrent</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Microcurrent Stimulator + Silverlon</title>
          <description>Patients receiving active electrical stimulation (15-50 microamps) during treatment of skin donor sites with Silverlon wound contact dressing. Intervention is active electrical stimulation via microcurrent stimulator.
Microcurrent stimulator: Microcurrent stimulation from 15-50 microamps
Silverlon Wound Contact Dressing: Silver coated nylon dressing FDA approved for use on donor sites in burn patients</description>
        </group>
        <group group_id="P2">
          <title>Silverlon Alone</title>
          <description>Patients receiving treatment of skin donor sites with Silverlon wound contact dressing alone (i.e., without active electrical stimulation)
Silverlon Wound Contact Dressing: Silver coated nylon dressing FDA approved for use on donor sites in burn patients</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Deviations</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Microcurrent Stimulator + Silverlon</title>
          <description>Patients receiving active electrical stimulation (15-50 microamps) during treatment of skin donor sites with Silverlon wound contact dressing.
Intervention is active electrical stimulation via microcurrent stimulator.
Microcurrent stimulator: Microcurrent stimulation from 15-50 microamps Silverlon Wound Contact Dressing: Silver coated nylon dressing FDA approved for use on donor sites in burn patients</description>
        </group>
        <group group_id="B2">
          <title>Silverlon Alone</title>
          <description>Patients receiving treatment of skin donor sites with Silverlon wound contact dressing alone (i.e., without active electrical stimulation)
Silverlon Wound Contact Dressing: Silver coated nylon dressing FDA approved for use on donor sites in burn patients</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.8" spread="9.5"/>
                    <measurement group_id="B2" value="33.8" spread="9.5"/>
                    <measurement group_id="B3" value="33.8" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Wound Healing</title>
        <description>Time to 90% confluent reepitheliazation of donor site, as indicator of wound healing</description>
        <time_frame>20 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Microcurrent Stimulator + Silverlon</title>
            <description>Patients receiving active electrical stimulation (15-50 microamps) during treatment of skin donor sites with Silverlon wound contact dressing. Intervention is active electrical stimulation via microcurrent stimulator.
Microcurrent stimulator: Microcurrent stimulation from 15-50 microamps
Silverlon Wound Contact Dressing: Silver coated nylon dressing FDA approved for use on donor sites in burn patients</description>
          </group>
          <group group_id="O2">
            <title>Silverlon Alone</title>
            <description>Patients receiving treatment of skin donor sites with Silverlon wound contact dressing alone (i.e., without active electrical stimulation)
Silverlon Wound Contact Dressing: Silver coated nylon dressing FDA approved for use on donor sites in burn patients</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Wound Healing</title>
          <description>Time to 90% confluent reepitheliazation of donor site, as indicator of wound healing</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" lower_limit="7" upper_limit="15"/>
                    <measurement group_id="O2" value="11.1" lower_limit="8" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Microcurrent Stimulator + Silverlon</title>
          <description>Patients receiving active electrical stimulation (15-50 microamps) during treatment of skin donor sites with Silverlon wound contact dressing. Intervention is active electrical stimulation via microcurrent stimulator.
Microcurrent stimulator: Microcurrent stimulation from 15-50 microamps
Silverlon Wound Contact Dressing: Silver coated nylon dressing FDA approved for use on donor sites in burn patients</description>
        </group>
        <group group_id="E2">
          <title>Silverlon Alone</title>
          <description>Patients receiving treatment of skin donor sites with Silverlon wound contact dressing alone (i.e., without active electrical stimulation)
Silverlon Wound Contact Dressing: Silver coated nylon dressing FDA approved for use on donor sites in burn patients</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <description>IRB found not to be attributable to study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis (DVT)</sub_title>
                <description>Institutional Review Board (IRB) found not to be attributable to study.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Leopoldo C. Cancio, COL, MC</name_or_title>
      <organization>USAISR</organization>
      <phone>210-916-3301</phone>
      <email>leopoldo.c.cancio.mil@mail.mil</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

